PaxMedica to Present at the Jan 26th Virtual Investor Summit Microcap Event
PaxMedica, Inc. (Nasdaq: PXMD) announced its participation in the Virtual Investor Summit on January 26, 2023, at 1:30 PM EST. The summit will feature 25 micro-cap companies with strong market performance, allowing qualified investors to engage in one-on-one sessions. PaxMedica focuses on developing anti-purinergic drug therapies for neurologic disorders, including Autism Spectrum Disorder and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. The company aims to advance its lead program, PAX-101, an intravenous formulation of suramin, targeting ASD and exploring its potential against Long COVID-19 Syndrome.
- Participation in Virtual Investor Summit may enhance visibility and investor interest.
- Focus on innovative therapies for high-demand medical conditions like ASD and ME/CFS.
- Clinical stage, indicating potential risks and uncertainties in drug development.
- Dependence on a single lead program, PAX-101, poses risks if program faces setbacks.
Presentation on Thursday, January 26th, 2023 at 1:30 PM EST
TARRYTOWN, NY, Jan. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that it will be presenting virtually at the upcoming Virtual Investor Summit on January 26th.
Event: Q1 Investor Summit
Date: Thursday, January 26th, 2023
Presentation: January 26th at 1:30 PM ET
Location: https://us06web.zoom.us/webinar/register/WN_LRZ8iM38TTCNpbbgvkUvCA
- The theme is 25 micro-cap companies with a catalyst and/or strong performance in the current market
- 1x1s will be available for qualified investors
- The conference is completely complimentary to qualified investors. Please register at Complimentary Investor Registration
About PaxMedica
PaxMedica is a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including Autism Spectrum Disorder (“ASD”), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (“ME/CFS”), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (“COVID-19”). One of PaxMedica’s primary points of focus is the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders such as ME/CFS and Long COVID-19 Syndrome, a clinical diagnosis in individuals who have been previously infected with COVID-19. For more information, please visit: www.paxmedica.com
About the Investor Summit
The Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q1 Investor Summit will take place virtually, featuring 30 companies and over 120 institutional, family office, and high net worth investors. Sectors Participating: Biotech, Communication Services, Consumer, Energy, Technology, Financial, Healthcare, Industrials, Materials, Real Estate. Contact: emily@investorsummitgroup.com
Contacts:
Stephanie Prince
PCG Advisory
sprince@pcgadvisory.com
(646) 863-6341
FAQ
When will PaxMedica present at the Virtual Investor Summit?
What is the focus of PaxMedica's drug development?
What is PaxMedica's lead program?
What types of investors can register for the Investor Summit?
